Actively Recruiting
A Study on COPD Phenotypes, Endotypes and Treatable Traits
Led by Chinese University of Hong Kong · Updated on 2025-05-04
460
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes.The recognition of COPD phenotypes and endotypes has significantly impacted the management of the disease. Furthermore, treatable traits (TTs) are recognizable phenotypic or endotypic characteristics that can be assessed and successfully targeted by therapy to improve a clinical outcome in a patient with airway disease. The healthcare system in Hong Kong is different from that of other places. Previous studies in Hong Kong only looked at specific endotypes; an example is the eosinophils cut-off to predict COPD exacerbations and the treatment effect of applying interventions to certain phenotypes, e.g. approaching the exacerbation phenotype with a comprehensive care programme. There is not much information on the overall phenotypes, endotypes, and TTs of COPD patients in Hong Kong. The characteristics of the patients would help to further assess whether the multi-TT approach can improve their outcomes. This study aims to assess 1. the phenotypes, endotypes and treatable traits of COPD patients over time 2. Outcome of patients according to their phenotypes, endotypes and treatable traits over a period of 3 years. 4\) Clustering analyses will also be employed to assess groups of patients with similar characteristics and to assess the change in their outcome over time.
CONDITIONS
Official Title
A Study on COPD Phenotypes, Endotypes and Treatable Traits
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with COPD confirmed by chronic respiratory symptoms and lung function showing a post-bronchodilator FEV1/FVC less than 70%
- Patient is 40 years of age or older
You will not qualify if you...
- Presence of serious disease that would prevent follow-up for 3 years, such as late-stage cancer, severe heart failure, or severe renal failure not on dialysis
- Unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
F
Fanny WS Ko, MD
CONTACT
D
David SC Hui, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here